NASD · Healthcare · Drug Manufacturers - General · USA
AMGEN Inc is a mega cap company (market value over $200 billion) in the Drug Manufacturers - General industry.
Amgen discovers, develops, manufactures and delivers therapeutic medicines to address diseases with significant unmet medical needs. The company operates in human therapeutics, marketing products including Prolia for osteoporosis, Repatha for cardiovascular disease, and Otezla for psoriasis and psoriatic arthritis. Amgen serves healthcare providers and pharmaceutical distributors worldwide.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the AMGEN Inc stock.
Slightly overvalued: intrinsic value $366.90 per share, market price $424.94, margin of safety -15.8% (as of 2026-10-19).
Discounting its cash flows at 7.7% (average of 3 methods) values the shares at $366.90; the price of $424.94 is 16% above that value, and 81% of that value comes from beyond year five.
Leak Score: 43/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
2 more in this industry show a wider margin of safety.
AMGN is slightly overvalued (as of the 2026-10-19 close). Discounting its cash flows at 7.7% (average of 3 methods) values the shares at $366.90; the price of $424.94 is 16% above that value, and 81% of that value comes from beyond year five.
$366.90 per share (as of the 2026-10-19 close), against a market price of $424.94. That is a margin of safety of -15.8%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for roughly the growth the company has already delivered. No miracle needed, no discount either. Yearly sales growth the price needs: 11.8%. Yearly sales growth it has sustained: 7.1%.
43 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.